| Original language | English (US) |
|---|---|
| Pages (from-to) | 151-152 |
| Number of pages | 2 |
| Journal | American heart journal |
| Volume | 195 |
| DOIs | |
| State | Published - Jan 2018 |
| Externally published | Yes |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice : An NCDR Research to Practice (R2P) project. / Hess, Paul L.; Kennedy, Kevin; Cowherd, Michael; Virani, Salim S.; Masoudi, Frederick A.; Navar, Ann Marie; Yeh, Robert W.; Ho, P. Michael; Maddox, Thomas M.
In: American heart journal, Vol. 195, 01.2018, p. 151-152.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice
T2 - An NCDR Research to Practice (R2P) project
AU - Hess, Paul L.
AU - Kennedy, Kevin
AU - Cowherd, Michael
AU - Virani, Salim S.
AU - Masoudi, Frederick A.
AU - Navar, Ann Marie
AU - Yeh, Robert W.
AU - Ho, P. Michael
AU - Maddox, Thomas M.
N1 - Funding Information: This research was supported by the American College of Cardiology National Cardiovascular Data Registry. The PINNACLE Registry is an initiative of the American College of Cardiology. Bristol-Myers Squibb and Pfizer Inc are founding sponsors of the PINNACLE Registry. The PINNACLE Registry and the National Cardiovascular Data Registry had no role in the design or conduct of the study, the management or analysis performed in the study, or the interpretation of the data. Dr Masoudi is the Chief Medical Officer for the NCDR. Dr. Navar is supported by the National Heart, Lung, and Blood Institute (K01HL133416), and reports research support from Regeneron/Sanofi, and Amgen, Inc., and support as a consultant for Sanofi and Amgen, Inc. Other authors have no relevant disclosures. Funding Information: This research was supported by the American College of Cardiology National Cardiovascular Data Registry . The PINNACLE Registry is an initiative of the American College of Cardiology. Bristol-Myers Squibb and Pfizer Inc are founding sponsors of the PINNACLE Registry. The PINNACLE Registry and the National Cardiovascular Data Registry had no role in the design or conduct of the study, the management or analysis performed in the study, or the interpretation of the data. Dr Masoudi is the Chief Medical Officer for the NCDR. Dr. Navar is supported by the National Heart, Lung, and Blood Institute (K01HL133416), and reports research support from Regeneron/Sanofi, and Amgen, Inc., and support as a consultant for Sanofi and Amgen, Inc. Other authors have no relevant disclosures.
PY - 2018/1
Y1 - 2018/1
UR - http://www.scopus.com/inward/record.url?scp=85032885957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032885957&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2017.09.004
DO - 10.1016/j.ahj.2017.09.004
M3 - Letter
C2 - 29224643
AN - SCOPUS:85032885957
VL - 195
SP - 151
EP - 152
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
ER -